Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma

British Journal of Cancer

Volumn 91, Issue 4, 2004, Pages 753-759

  Park, S W ^a   Ludes Meyers, J ^b   Zimonjic, D B ^a   Durkin, M E ^a   Popescu, N C ^a,c   Aldaz, C M ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Building 37 ^*  (United States)

Author keywords

Chromosome rearrangements; Fragile sites; Hepatocellular carcinoma; Tumour suppressor gene; WWOX gene expression

Indexed keywords

ARTICLE; CHROMOSOME BANDING PATTERN; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; EXON; GENE DELETION; GENE EXPRESSION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 4344715921     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602023     Document Type: Article

References (38)

1. Aqeilan RI, Pekarsky Y, Herrero JJ, Palamarchuk A, Letofsky J, Druck T, Trapasso F, Han S-Y, Melino G, Huebner K, Croce CM (2004) Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. PNAS 101: 4401-4406
2. Arlt MF, Casper AM, Glover TW (2003) Common fragile sites. Cytogenet Genome Res 100: 92-100
3. Balsara BR, Pei J, De Rienzo A, Simon D, Tosolini A, Lu YY, Shen FM, Fan X, Lin WY, Buetow KH, London WT, Testa JR (2001) Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. Genes Chromosomes Cancer 30: 245-253
4. Bednarek AK, Keck-Waggoner CL, Daniel RL, Laflin KJ, Bergsagel PL, Kiguchi K, Brenner AJ, Aldaz CM (2001) WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 61: 8068-8073
5. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM (2000) WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 60: 2140-2145
6. Bishop JM (1987) The molecular genetics of cancer. Science 235: 305-311
7. Casper AM, Nghiem P, Arlt MF, Glover TW (2002) ATR regulates fragile site stability. Cell 111: 779-789
8. Croce CM, Sozzi G, Huebner K (1999) Role of FHIT in human cancer. J Clin Oncol 17: 1618-1624
9. Denison SR, Simper RK, Greenbaum IF (2003) How common are common fragile sites in humans: interindividual variation in the distribution of aphidicolin-induced fragile sites. Cytogenet Genome Res 101: 8-16
10. Driouch K, Prydz H, Monese R, Johansen H, Lidereau R, Frengen E (2002) Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene 21: 1832-1840
11. Glover TW, Berger C, Coyle J, Echo B (1984) DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet 67: 136-142
12. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70
13. Huebner K, Croce CM (2001) FRA3B and other common fragile sites: the weakest links. Nat Rev Cancer 1: 214-221
14. Ishii H, Vecchione A, Furukawa Y, Sutheesophon K, Han S-Y, Druck T, Kuroki T, Trapasso F, Nishimura M, Saito Y, Ozawa K, Croce CM, Huebner K, Furukawa Y (2003) Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res 1: 940-947
15. Keck CL, Zimonjic DB, Yuan BZ, Thorgeirsson SS, Popescu NC (1999) Nonrandom breakpoints of unbalanced chromosome translocations in human hepatocellular carcinoma cell lines. Cancer Genet Cytogenet 111: 37-44
16. Kuroki T, Trapasso F, Shiraishi T, Alder H, Mimori K, Mori M, Croce CM (2002) Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res 62: 2258-2260
17. Laird C, Jaffe E, Karpen G, Lamb M, Nelson R (1987) Fragile sites in chromosomes as regions of late replicating DNA. Trends Genet 3: 274-281
18. Laird PW, Zijderveld A, Linders K, Rudnicki MA, Jaenisch R, Berns A (1991) Simplified mammalian DNA isolation procedure. Nucleic Acids Res 19: 4293
19. Le Beau MM, Rassool FV, Neilly ME, Espinosa R, Glover TW, Smith DI, McKeithan TW (1998) Replication of a common fragile site, FRA3B, occurs late in S phase and is delayed further upon induction: implications for the mechanism of fragile site induction. Hum Mol Genet 7: 755-761
20. Ludes-Meyers JH, Bednarek AK, Popescu NC, Bedford M, Aldaz CM (2003) WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res 100: 101-110
21. Ming L, Thorgeirsson SS, Gail MH, Lu P, Harris CC, Wang N, Shao Y, Wu Z, Liu G, Wang X, Sun Z (2002) Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 36: 1214-1220
22. Mitelman F, Mertens F, Johansson B (1997) A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 15: 417-474
23. Paige AJ, Taylor KJ, Taylor C, Hillier SG, Farrington S, Scott D, Porteous DJ, Smyth JF, Gabra H, Watson JE (2001) WWOX: a candidate tumor suppressor gene involved in multiple tumor types. PNAS 98: 11417-11422
24. Palakodeti A, Han Y, Jiang Y, Le Beau MM (2004) The role of late/slow replication of the FRA16D in common fragile site induction. Genes Chromosomes Cancer 39: 71-76
25. Park S-W, Durkin ME, Thorgeirsson SS, Popescu NC (2003) DNA variants of DLC-1, a candidate tumor suppressor gene in human hepatocellular carcinoma. Int J Oncol 23: 133-137
26. Popescu NC (2003) Genetic alterations in cancer cells as a result of breakage at fragile sites. Cancer Lett 192: 1-17
27. Smith DI, Huang H, Wang L (1998) Common fragile sites and cancer. Int J Oncol 12: 187-196
28. Thorgeirsson SS, Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31: 339-346
29. Turner B, Ottey M, Zimonjic DB, Potoczek M, Hauck WW, Pequignot E, Keck-Waggoner CL, Sevignani C, Aldaz CM, McCue PA, Palazzo J, Huebner K, Popescu NC (2002) The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers. Cancer Res 62: 4054-4060
30. Watanabe A, Hippo Y, Taniguchi H, Iwanari H, Yashiro M, Hirakawa K, Kodama T, Aburatani H (2003) An opposing view on WWOX protein function as a tumor suppressor. Cancer Res 63: 8629-8633
31. Yakicier MC, Legoix P, Vaury C, Gressin L, Tubacher E, Capron F, Bayer J, Degott C, Balabaud C, Zucman-Rossi J (2001) Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma. Oncogene 20: 5232-5238
32. Yendamuri S, Kuroki T, Trapasso F, Henry AC, Dumon KR, Huebner K, Williams NN, Kaiser LR, Croce CM (2003) WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res 63: 878-881
33. Yuan B-Z, Keck-Waggoner C, Zimonjic DB, Thorgeirsson SS, Popescu NC (2000) Alterations of the FHIT gene in human hepatocellular carcinoma. Cancer Res 60: 1049-1053
34. Yuan B-Z, Zhou X, Durkin ME, Zimonjic DB, Gumundsdottir K, Eyfjord JE, Thorgeirsson SS, Popescu NC (2003a) DLC-1 gene inhibits human breast cancer cell growth with in vivo tumorigenicity. Oncogene 22: 445-450
35. Yuan B-Z, Zhou X, Zimonjic DB, Durkin ME, Popescu NC (2003b) Amplification and overexpression of the EMS I oncogene, a possible prognostic marker, in human hepatocellular carcinoma. J Mol Diagn 5: 48-53
36. Zhou X, Thorgeirsson SS, Popescu NC (2004) Restoration of DLC-1 expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene 23: 1308-1313
37. Zimonjic DB, Durkin ME, Keck-Waggoner CL, Park S-W, Thorgeirsson SS, Popescu NC (2003) SMAD5 gene expression, rearrangements, copy-number, and amplification at fragile site FRA5C in human hepatocellular carcinoma. Neoplasia 5: 390-396
38. Zimonjic DB, Keck CL, Thorgeirsson SS, Popescu NC (1999) Novel recurrent genetic imbalances in human hepatocellular carcinoma cell lines identified by comparative genomic hybridization. Hepatology 29: 1208-1214